280 results
Page 3 of 14
6-K
EX-99.1
jp31a4hjyx294z38p
1 Aug 22
Current report (foreign)
4:48pm
D
f5w3ot2nxf3
29 Jul 22
$34.64M in equity, sold $34.64M, 4 investors
6:15pm
6-K
EX-99.1
zxratktc
19 Jul 22
Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
9:01am
6-K
EX-2.1
xdnltdrzr4jourd
19 Jul 22
Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
9:01am
6-K
EX-10.4
kth7s8l
8 Jul 22
Current report (foreign)
8:58am
6-K
EX-10.3
tjznauuhe2
8 Jul 22
Current report (foreign)
8:58am
6-K
EX-2.1
dkazqx3
8 Jul 22
Current report (foreign)
8:58am
6-K
EX-99.1
axhyat44q 2yg
7 Jul 22
Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway
8:30am
6-K
EX-99.1
6shnaezgnkfyuwh cgf
23 Jun 22
Territory of the British Virgin Islands
4:05pm
6-K
EX-99.1
gq4jhazi3sorf91dm8
31 Mar 22
Portage Biotech Provides Update on Clinical-Stage and Development Programs
8:00am
20-F/A
9surwj3
3 Mar 22
Annual report (foreign) (amended)
6:57pm
6-K
EX-99.2
r4p04
25 Feb 22
Current report (foreign)
5:29pm
6-K
EX-99.1
vkz8ivy08se70
25 Feb 22
Current report (foreign)
5:29pm